In the Cox proportional hazards regression analysis adjusted for age, sex, and EGFR mutation status, the IL-6 rs1800796G allele remained an independent factor influencing OS in NSCLC patients on osimertinib therapy (adjusted HR for G allele vs. C/C: 6.38 (95% CI: 1.32–30.6), P = 0.021). This evidence concerns the gene IL6 and non-small cell lung carcinoma.